ArticleArthritis care & research2020
Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study.
Article in Arthritis care & research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pooled it
- Assessment of markers of primary aldosteronism in systemic sclerosis and their relationships with renal and cardiovascular outcomes.RMD open · 2026Article
- Anti-endothelin receptor A autoantibodies associate with immunovascular risk and activate endothelial signalling in SLE.Lupus science & medicine · 2026Article
- Evaluation of Hypertension in Pediatric Patients With Systemic Lupus Erythematosus: A Historical Study.International journal of hypertension · 2026Article
- Article
- Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There a Common Basis?Life (Basel, Switzerland) · 2024Review
- Vascular damage in systemic lupus erythematosus.Nature reviews. Nephrology · 2024Review
- Hypertension in connective tissue disease.Journal of human hypertension · 2024Review
- Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus and Associated with Lower 24-Hour Blood Pressure.Frontiers in lupus · 2024Article
- Phenotype Risk Score but Not Genetic Risk Score Aids in Identifying Individuals With Systemic Lupus Erythematosus in the Electronic Health Record.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Risk of End-Stage Renal Disease in Patients With Systemic Lupus Erythematosus and Diabetes Mellitus: A Danish Nationwide Cohort Study.Arthritis care & research · 2023Article
- Article
- The Outcomes of an e-Wellness Program for Lupus Patients in Thailand: A Participatory Action Research Approach.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2023Article
- Systemic Lupus Erythematosus Delivery Outcomes Are Unchanged Across Three Decades.ACR open rheumatology · 2022Article
- Resistant hypertension and PRES syndrome induced by carbamazepine in a patient with SLE: A case report and literature review.Annals of medicine and surgery (2012) · 2022Article
- Cardiovascular Outcomes in Systemic Lupus Erythematosus.Current cardiology reports · 2022Review
- Should Renal Inflammation Be Targeted While Treating Hypertension?Frontiers in physiology · 2022Review
- Treatment patterns and control of hypertension in systemic lupus erythematosus (SLE): a cross-sectional study.BMJ open · 2021Article
- Autoimmune-mediated renal disease and hypertension.Clinical science (London, England : 1979) · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo compare the risk of resistant hypertension (RHTN) in patients with systemic lupus erythematosus (SLE) and in controls without SLE, and to define factors associated with RHTN in patients with SLE.
methodsWe studied 1,044 patients with SLE and 5,241 control subjects using de-identified electronic health records from a tertiary care center. SLE was defined as ≥4 International Classification of Diseases, Ninth Revision codes for SLE and antinuclear antibody titer ≥1:160. RHTN was defined as uncontrolled blood pressure on 3 antihypertensive medications or requiring 4 or more antihypertensives to attain control. First, we compared the risk of RHTN between groups. Second, we examined the association between RHTN and all-cause mortality in patients with SLE.
resultsRHTN was nearly twice as prevalent in patients with SLE compared to control subjects (10.2% and 5.3%, respectively), with an incidence rate of 10.2 versus 6.1 cases per 1,000 person-years of observation (hazard ratio [HR] 1.72 [95% confidence interval 1.28-2.30]; P < 0.001, adjusted for age, sex, race, baseline end-stage renal disease [ESRD], creatinine, and calendar year). In patients with SLE, we found associations between RHTN and black race, lower renal function, hypercholesterolemia, and increased inflammatory markers. RHTN was associated with a significantly higher mortality risk (HR 2.91, P = 0.0005) after adjustment for age, sex, race, calendar year, creatinine, baseline ESRD, and number of visits.
conclusionPatients with SLE have a higher risk of RHTN compared to frequency-matched controls, independent of multiple covariates. RHTN is an important comorbidity for clinicians to recognize in SLE, because it is associated with a higher risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.